|
| 31537750 | Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. | Pharmacol Rev | 2019 |
| 30167735 | Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. | Diabetologia | 2019 |
| 29429979 | Who let the dogs out? The ever-present threat of autoreactive T cells. | Sci Immunol | 2018 |
| 29473705 | Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics. | Pediatr Diabetes | 2018 |
| 28844471 | Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes. | Cell Immunol | 2017 |
| 28198767 | Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs. | Transplantation | 2017 |
| 29348821 | Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. | Oncotarget | 2017 |
| 26225763 | Immune interventions to preserve β cell function in type 1 diabetes. | J Investig Med | 2016 |
| 28664195 | Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. | Sci Immunol | 2016 |
| 26518356 | Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes. | Eur J Immunol | 2016 |
| 27208317 | Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. | Diabetes Care | 2016 |
| 27209482 | Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial. | Clin Ther | 2016 |
| 26718498 | A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice. | Diabetes | 2016 |
| 27068279 | Strategies for clinical trials in type 1 diabetes. | J Autoimmun | 2016 |
| 27053235 | Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. | Diabetologia | 2016 |
| 26193635 | Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. | J Clin Invest | 2015 |
| 26370695 | Targeting memory T cells in type 1 diabetes. | Curr Diab Rep | 2015 |
| 24251641 | Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12â¿¿weeks in patients with type 2 diabetes mellitus. | Diabetes Obes Metab | 2014 |
| 24983393 | Targeted immune interventions for type 1 diabetes: not as easy as it looks! | Curr Opin Endocrinol Diabetes Obes | 2014 |
| 24795433 | Restoring the balance: immunotherapeutic combinations for autoimmune disease. | Dis Model Mech | 2014 |
| 24854541 | Immune-modulating effects of alpha-1 antitrypsin. | Biol Chem | 2014 |
| 23351021 | Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design. | Clin Exp Pharmacol Physiol | 2013 |
| 24622414 | Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. | Lancet Diabetes Endocrinol | 2013 |
| 24622416 | Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. | Lancet Diabetes Endocrinol | 2013 |
| 23835333 | Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. | Diabetes | 2013 |
| 23686914 | C domain-selective inhibition of angiotensin-converting enzyme. | J Renin Angiotensin Aldosterone Syst | 2013 |
| 23405091 | Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. | PLoS One | 2013 |
| 23510726 | Anti-cytokine therapies in T1D: Concepts and strategies. | Clin Immunol | 2013 |
| 22668937 | Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme. | S Afr Med J | 2012 |
| 23804273 | Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. | Rev Diabet Stud | 2012 |
| 22721971 | Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. | Diabetes | 2012 |
| 21362122 | Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. | Diabetes Obes Metab | 2011 |
| 20477411 | Pacific biomarkers, inc. | Biomark Med | 2008 |
| 16895474 | Homologous substitution of ACE C-domain regions with N-domain sequences: effect on processing, shedding, and catalytic properties. | Biol Chem | 2006 |
| 17044798 | Safety issues associated with the use of angiotensin-converting enzyme inhibitors. | Expert Opin Drug Saf | 2006 |
| 15813703 | The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. | Biochem J | 2005 |
| 14751227 | Deletion of the cytoplasmic domain increases basal shedding of angiotensin-converting enzyme. | Biochem Biophys Res Commun | 2004 |
| 12542396 | Deglycosylation, processing and crystallization of human testis angiotensin-converting enzyme. | Biochem J | 2003 |
| 14605997 | Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. | Horm Metab Res | 2003 |
| 14668810 | Ace revisited: a new target for structure-based drug design. | Nat Rev Drug Discov | 2003 |
| 12610046 | Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. | Diabetes Care | 2003 |
| 12860201 | Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. | Peptides | 2003 |
| 12366866 | Mycosin-1, a subtilisin-like serine protease of Mycobacterium tuberculosis, is cell wall-associated and expressed during infection of macrophages. | BMC Microbiol | 2002 |
| 12372418 | Defining the boundaries of the testis angiotensin I-converting enzyme ectodomain. | Biochem Biophys Res Commun | 2002 |
| 11485566 | Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding. | Biochem J | 2001 |
| 11322496 | Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program. | Endocrine | 2001 |
| 11747437 | Cleavage of disulfide-bridged stalk domains during shedding of angiotensin-converting enzyme occurs at multiple juxtamembrane sites. | Biochemistry | 2001 |
| 10758405 | CR3: a general purpose adhesion-recognition receptor essential for innate immunity. | Microbes Infect | 2000 |
| 10974545 | The mycosins of Mycobacterium tuberculosis H37Rv: a family of subtilisin-like serine proteases. | Gene | 2000 |
| 10769174 | Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. | Biochem J | 2000 |